For healthcare professionals only

Letters

BMJ may have hyped CURE study

BMJ 2003; 326 doi: https://doi.org/10.1136/bmj.326.7400.1211-b (Published 29 May 2003) Cite this as: BMJ 2003;326:1211
  1. Martin G Duerden, general practitioner (martin{at}theduerdens.co.uk)
  1. Meddygfa Gyffin, Conwy LL32 8LT

    EDITOR—The 12 562 patient study presented in such exciting terms as a news feature in March is none other than a reanalysis of the CURE study, which was originally published in the New England Journal of Medicine in August 2001.1 2 It is not a new study.

    At the time of the original publication the study received immense media interest, which had the taint of marketing hype as it seemed to blow the results out of proportion.3 I'm not convinced that this Circulation reanalysis tells us much more than we knew already.4 It is important to recognise the specific licensed indication for the combination of aspirin and clopidogrel— specifically for treatment of unstable angina or non-Q wave myocardial infarction.

    Has the BMJ unwittingly contributed to the hype?

    Footnotes

    • Competing interests MGD has spoken at educational meetings partly sponsored by Bristol Myers Squibb, which co-markets clopidogrel.

    References

    1. 1.
    2. 2.
    3. 3.
    4. 4.
    View Abstract

    Log in

    Log in through your institution

    Subscribe

    * For online subscription